Atreon Orthopedic receives FDA approval for Rotium Bioresorbable Wick!

Today, Atreon Orthopedics announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Rotium Bioresorbable Wick, which is intended to be used in conjunction with suture anchors for the reattachment of tendon to bone in rotator cuff repairs

Rotium Bioresorbable Wick is a a non-woven, microfiber matrix comprising biodegradable polymer fibers that mimic the extracellular matrix structure. Rotium™ supports cellular infiltration and migration, and facilitates functional tissue regeneration.

RenovoDerm Poster Presented at WOW Conference

RenovoDerm’s first product, the Phoenix Wound Matrix®, was featured by Dr. Michael S. Miller at the Wild on Wounds conference today! Wild on Wounds (WOW) is a national wound conference designed for healthcare professionals interested in skin and wound management.

Jed Johnson Published in HDIAC Journal: Volume 5 Issue 2

ParaGen's CTO Jed Johnson and Ikove Capital's Amy Jackson published an article in the most recent issue of the HDIAC Journal! Read "Tissue Engineering for a Better Tomorrow" by clicking the link below.

RenovoDerm Holds Executive Reimbursement Workshop

On July 25, RenovoDerm held an all-day executive reimbursement workshop led by Kathleen Schaum, President of Kathleen D. Schaum & Assoc., Inc. Ms. Schaum is a nationally recognized wound care reimbursement strategy consultant and educator with nearly 50 years of industry experience. Ms. Schaum led the RenovoDerm team in crafting its reimbursement strategy for the Phoenix Wound Care Matrix, which included coding, coverage, and payment. The seminar also focused on identifying and targeting the most applicable markets for the Phoenix and creating a detailed timeline to achieve a product launch.

The workshop was very successful. After significant dialogue with Ms. Schaum, the RenovoDerm team is now better equipped to effectively earn a strategic reimbursement code, implement a detailed sales and marketing strategy, and utilize valuable resources to maximize the company’s value.

Announcing ParaGen's New Project Manager: Austin Laue!

Austin Laue is a project manager for ParaGen Technologies. Previously, Austin worked for Lockheed Martin in finance and procurement roles. Austin earned his BSBA in Operations Management with an International Studies minor from The Ohio State University in 2016.  He is from Rockford, IL and is passionate about fitness, food, water sports, coaching youth sports, and the NBA.

ParaGen Team Attends the Rev1 Ventures Innovation Hop

The ParaGen team recently participated in the fourth annual Innovation Hop at Rev1 Ventures. The event highlights growing Columbus startups and entrepreneurs, along with connecting those startups and entrepreneurs with their community.

Jed Johnson to Attend the Regenerative Medicine Stakeholder's Meeting

Due to his expertise in the field of regenerative medicine, ParaGen's Jed Johnson was invited to attend the Regenerative Medicine Stakeholder's meeting taking place April 11-12, 2018 at the Bolger Center, Potomac, MD on behalf of the Clinical and Rehabilitative Medicine Research Program. 

Jed Johnson at the American Society of Pediatric Otolaryngology Annual Seminar

Jed Johnson, Ph.D. will discuss the pathways (and barriers) to bringing tissue engineered constructs to the bedside. He will explore the role of clinical collaborations, as well as the regulatory challenges with commercialization:

• Advantages of clinical collaborations: experience, facilities, patient populations
• Regulatory challenges: synthetic devices, cell-based devices, combination devices
• Funding challenges: animal studies, ISO 10993 biocompatibility studies, clinical trials
• Commercialization challenges: reimbursement, sales channels, manufacturing scale-up, cost

Dr. Cohen to Host Talk on Robotic-Assisted Surgery

ParaGen medical director Dr. Cohen will be holding a health talk tomorrow on robotic assisted surgery! Check out Adena Health System’s website for more details.

RenovoDerm receives FDA approval for Phoenix Wound Matrix!

Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix, which is a wound care device that accelerates the body’s healing response, facilitates tissue growth and regeneration, reduces scar formation and enhances overall cosmesis.

The Phoenix Wound Matrix is a fully resorbable synthetic graft that closely mimics the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.